New Perspectives in Mathematical Modeling Focusing on the Type of the Immune Response and Cancer Eradication

Badou A[1], Bellouquid A[2]* and CH-Chaoui M[2]

[1]Genetics and Molecular Pathology Laboratory, Casablanca Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco

[2]Ecole Nationale des Sciences Appliquées, Cadi Ayyad University, Marrakech, Morocco

*Corresponding author: Bellouquid A, Ecole Nationale des Sciences Appliquées, Cadi Ayyad University, Marrakech, Morocco, E-mail: a.bellouquid@uca.ma

Abstract

Tumor progression is characterized by the interaction between the tumor and immune system cells in a particular microenvironment. Recently, the involvement of immune cells either favorably or unfavorably was confirmed; and it seems that much would depend on the type of the immune response generated for each individual patient. This note deals with the perspective of modeling of the onset and the progression of cancer, depending on the nature of the patient's immune response, using tools of kinetic theory for active particle, developed recently to overcome the complexity of biological systems. Mathematical models can act, once validated, as in silico laboratories. This approach would result in a less expensive design of new treatments, based on specific stimulation of the patient's efficient type of the immune response against tumors.

Introduction

Cancer can be viewed as a complex disease where cells of the same genotype generate, during cell cycle progression, daughter cells characterized by the acquisition of new hallmarks. While healthy cells finely control proliferation-triggering signals that instruct entry into cell division cycle, cancer cells progressively acquire new traits involving deregulation of these signals [1]. During progression of the disease, other cellular processes such as cell survival are also deregulated [1]. Conceptual progress in the field has, however, extended the biology of tumors beyond this simple notion of uncontrolled cell division. Progress in cancer research made it clear that the pathology encompass the contribution of other factors grouped in the "tumor microenvironment" [2]. Cells of the immune system constitute one major actor within this microenvironment [2]. In fact, tumor progression is characterized by interaction between the tumor and various cells of the immune system in this complex and intriguing microenvironment. In the last decade, the ability of cancer cells to escape recognition by immune cells has been added to main hallmarks that allow cancer cells to sustain their ability to survive and eventually evolve towards metastatic stages [1].

A mathematical theory exploring how evolution can be constructive and how natural selection can lead from lower to higher levels of organization is presented in [3]. This deals with a study of evolutionary game theory in a setting where individuals learn from each other. This biological framework is transferred into a general mathematical framework [4], where the modeling of the dynamics, at the cellular scale, is developed by methods of statistical dynamics and game theory. This approach was initiated [5] and subsequently developed by various authors [6-13]. It has been developed to describe the dynamics of large systems of interacting cells, called active particles [6], with their states called activity. This corresponds to genotype-phenotype expression, also called expression [12], and it is summarized by a scalar variable, ranging in a domain. $D_u \subseteq \mathbb{R}$.. The individuals corresponding to the same expression are grouped into functional subsystems or subpopulations, where the common tract is viewed as a functional expression that aims at survivance. The activity within subpopulation is the micro-state, which is heterogeneously distributed, while the overall state of the system is described by suitable distribution functions $f_i(t, u) : [0, \ T] \times D_u \rightarrow \mathbb{R}^+$ over the activity u, where $0 < T \leq \ +\infty$. The quantity $f_i(t, u) du$ represents the (infinitesimal) number of active particles of the ith subsystem having at time an activity comprised in the (infinitesimal) interval $[u; \ u + du]$. Under suitable integrality conditions, the quantities

$$v_i(t) = \int_{D_u} f_i(t, u) du \text{ and } A_i(t) = \int_{D_u} f_i(t, u) du$$ represent respectively the size and the activation in the ith subsystem at time . Consequently, it is fascinating to understand the behavior of theses quantities over time.

Pair interactions between active particles generate birth-death processes and, with relative small probability, modification of their expression, which amounts to the generation of a new subpopulation. The evolution of the system may depend not only on the interactions between living entities, but also on the interactions between living entities and the external surrounding environment. In more details, interactions involve three kinds of particles: candidate, test, and field [6]. The interaction rule is as follows: candidate particles can acquire, in probability, the state of the test particles, after an interaction with field particles, while test particles lose that state after interactions.

Let $f = (f_1, \ldots, \ f_n)$ the set of distributions functions. The structure, to be used as paradigm for the derivation of our model, is:

$$\partial_t f_i(t, u) = J_i[f](t, u) = C_i[f](t, u) + P_i[f](t, u) - \lambda_i[f_i]\left(f_i - \tilde{f}_i\right)(t, u) \ ,$$

for, $i = 1, \ldots, n$. Following the recent paper [13], the dynamics of distributions functions is obtained by a balance of particles due to the inlet and outlet flows in the elementary volume $[u; \ u + du]$ of the space of micro-state . The said fluxes are determined by the dynamics of interactions, which involve candidate, field and test particles. More specifically, two types of interactions are considered, conservative interactions (modeled by $C_i[f]$), when particles modify only their microscopic state, corresponding to an early stage of competition, and non-conservative interactions modeled by $P_i[f]$, when interactions generate proliferation or destruction of particles in their microscopic state. $\lambda_i[f_i]$ refers to the natural decay of each subpopulation towards

a level distribution $\tilde{f}_i$, or to a death process of the ith particle due to their natural extinction, where death occurs only within same subpopulation and state of the candidate particle. The reader interested on more details on the modeling approach is addressed to our previous works [13]. This provides a mathematical structure suitable to include a variety of specific biological dynamics such as the immune response in the presence of mutations and selection.

Now, we refer to biological systems involving the competition between cancer cells, carrier of the pathology, and effector immune cells. Cells of the immune system evolve and differentiate in time in order to acquire the ability of recognizing non-self-substances and learning to identify new pathogen agents or new dangers not previously encountered. The specialization of cells of the immune system plays a central role in coordinating the immune response to different categories of pathogens or other dangers including cancer cells. This specialization is manifested by the presence of different subpopulations of T cells that produce specific cytokines and display distinct functions. For example, the control of pathogens that are found in phagocytic cells requires the involvement of CD4+ T cells secreting IFNγ to activate antimicrobial mechanisms of the phagocyte [14]. These cells are generally referred to as Th1 "T helper type 1" cells [14]. However, the Th2 lymphocytes which produce IL-4, IL-5 and IL-13, are important in the control of extracellular parasites [14]. Another subpopulation of CD4+ T cells was identified and named Th17. These are characterized by the production of IL-17 [15], IL-17F, IL-21 and IL-22 [16-18], Th17 type cells were found to be key drivers of inflammation and tissue damage [19,20].

In the tumoral microenvironment, it appears that immune cells play a role in the prevention from the occurrence and progression of tumors [21]. In addition, it has been reported that the presence of T cells infiltrating the tumors is associated with improved survival in patients with colorectal [22], breast [23,24] and lung [25-28] cancers. However, the immune system, through the inflammatory process, could also be associated with tumor development [29,30].

More recently, it has been reported that the type of tumor infiltrating T lymphocytes and their density would be crucial [31]. Indeed, high densities of memory T cells in the intratumoral environment would correlate with decreasing incidence of early metastasis and would prevent remissions in patients with colorectal cancer [32]. In another study, the role of different subpopulations of T cells in colorectal cancer has been studied and it has been shown that patients with high expression of genes related to Th17 response exhibit a poor prognosis [32]. In contrast, patients with high expression of genes related to Th1 response had significantly prolonged survival [32]. However, the genes associated with Th2 and T regulatory type responses have no effect on disease progression [32]. Increased expression of IL-23 (a growth promoting cytokine of Th17 cells) but

not of IL-12 (cytokine involved in Th1 differentiation), was also reported in human tumors. Whereas IL-12 promotes the infiltration of cytotoxic T cells, IL-23 promotes inflammatory responses and increases angiogenesis, but reduces the infiltration of cytotoxic T cells [33]. In addition, the suppression of IL-23 in vivo in mice leads to increased infiltration of cytotoxic T cells in the tumor tissue, thereby promoting a protective effect against carcinogenesis. Furthermore, transplanted tumors also exhibit restricted growth in mice deficient in IL-23 or its receptor [33]. Altogether, these data indicate that the Th17 immune response promotes the growth of tumors; while cytotoxic T lymphocyte and Th1 type immune responses promote survival of cancer patients. Thus the type of the immune response developed within the tumor microenvironment is crucial and could, if it is the appropriate one, contribute to the eradication of the tumor. Therefore, attempts to develop mathematical models, whose consistency was verified via asymptotic behavior developed for solution and by numerical simulations, encompassing these immune findings would help in the prediction of cancer cell evolution and eventually eradication.

Acknowledgments

References

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.

2. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570.

3. Tarnita CE, Taubes CH, Nowak MA (2013) Evolutionary construction by staying together and coming together. J Theor Biol 320: 10-22.

4. Bellouquid A, De Angelis E, Knopoff D (2013) From the modeling of the immune hallmarks of cancer to a black swan in biology, Math Models Methods Appl Sci 23: 949-978.

5. Bellomo N, Preziosi L, Forni G (1996) A kinetic (cellular) theory for competition between tumors and the host immune system. J Biol Sys 4: 497-502.

6. Bellouquid A, Delitala M (2006) Mathematical Modeling of Complex Biological Systems. In: A Kinetic Theory Approach. Birkhäuser, Boston.

7. Bellouquid A (2015) From systems biology to analytic problems: Comment on the paper "On the interplay between mathematics and biology, hallmarks toward a new systems biology" by N. Bellomo et al. Phys Life Rev 12: 68-69.

8. Bellouquid A, CH-Chaoui M (2014) Asymptotic analysis of a nonlinear integro-differential system modeling the immune response. Comput Math Appl 68: 905-14.

9. Afraites L, Atlas A, Bellouquid A, CH-Chaoui M (2012) Modelling the complex immune system response to cancer cells. Mathematics in Engineering, Science and Aerospace 3: 269-283.

10. Jorcyk C L, Kolev M, Tawara K, Zubik-Kowal B (2012) Experimental versus numerical data for breast cancer progression, Nonlinear Analysis: Real World Applications 13: 78-84.

11. Bellouquid A, De Angelis E (2011) From Kinetic Models of Multicellular Growing Systems to Macroscopic Biological Tissue Models, Nonlinear Analysis: Real World Applications 12: 1111-1122.

12. Bellomo N, Elaiw A, Althiabi AM, Alghamdi MA, (2015), On the interplay between mathematics and biology, hallmarks toward a new systems biology. Phys Life Rev.

13. De Angelis E (2014) On the Mathematical Theory of Post-Darwinian Mutations, Selection, and Evolution. Mathematical Models and Methods in Applied Sciences 24: 2723-42.

14. Laurence A, O'Shea JJ (2007) T(H)-17 differentiation: of mice and men. Nat Immunol 8: 903-905.

15. Harrington LE, (2005) "Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages." Nat Immunol 11: 1123-1132.

16. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, et al. (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201: 233-240.

17. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, et al. (2006) Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203: 2271-2279.

18. Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, et al. (2007) IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448: 484-487.

19. Diveu C, McGeachy MJ, Cua DJ (2008) Cytokines that regulate autoimmunity. Curr Opin Immunol 20: 663-668.

20. Dong C (2008) Regulation and pro-inflammatory function of interleukin-17 family cytokines. Immunol Rev 226: 80-86.

21. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22: 329-360.

22. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.

23. Marrogi AJ, Munshi A, Merogi AJ, Ohadike Y, El-Habashi A, et al. (1997) Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 74: 492-501.

24. Menegaz RA, Michelin MA, Etchebehere RM, Fernandes PC, Murta EF (2008) Peri- and intratumoral T and B lymphocytic infiltration in breast cancer. Eur J Gynaecol Oncol 29: 321-326.

25. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, et al. (2008) Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 26: 4410-4417.

26. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, et al. (2006) Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 94: 275-280.

27. Ito N, Suzuki Y, Taniguchi Y, Ishiguro K, Nakamura H, et al. (2005) Prognostic significance of T helper 1 and 2 and T cytotoxic 1 and 2 cells in patients with non-small cell lung cancer. Anticancer Res 25: 2027-2031.

28. Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, et al. (2008) Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113: 1387-1395.

29. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867.

30. Balkwill F, Coussens LM (2004) Cancer: an inflammatory link. Nature 431: 405-406.

31. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, et al. (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654-2666.

32. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, et al. (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 71: 1263-1271.

33. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, et al. (2006) IL-23 promotes tumour incidence and growth. Nature 442: 461-465.